A brand new doable treatment to deal with coronavirus-positive sufferers might be sufficient to show the pandemic on its head, Fox News medical contributor Dr. Marc Siegel revealed Sunday on “Fox & Friends Weekend.”
First-stage testing of the experimental COVID-19 tablet known as Molnupiravir, by Merck and Ridgeback Biotherapeutics, confirmed promising indicators of effectiveness in lowering the virus in sufferers.
“It would be the holy grail on this as a result of it was simply studied in section two trials and it actually stopped the virus in its tracks,” he defined. “And there wasn’t any virus discovered within the sufferers that had been studied.”
The drug would perform as an at-home, five-day therapy, much like Tamiflu, to cease the virus from reproducing earlier than inflicting main injury. Siegel stated the therapeutic may come to market in as little as 4 to 5 months.
The physician stated although solely 182 sufferers had been studied throughout testing to date, the tablet may nonetheless be “very promising” for 1000’s of individuals.
“This is likely to be the longer term as soon as the vaccine actually will get management over the pandemic and we simply begin seeing remoted circumstances,” he stated. “By then, this drug is likely to be prepared and this is likely to be the drug for over the following a number of months.”
Siegel predicted the U.S. will probably be freed from the coronavirus pandemic by the summer season, making the Molnupiravir therapy “very useful” for managing remoted circumstances.
“This is the very first tablet that we’ve that’s one thing that we’d have the ability to use in our armamentarium in opposition to COVID as a therapeutic,” he stated.